All In Biotech

Drug Trial Radar · NCT07006805

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2026

Primary completion

Sep 2028

Study completion Oct 2029

Sponsor

Lead sponsor
Cabaletta BioIndustry
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis

Conditions

  • Relapsing Multiple Sclerosis (RMS)
  • Progressive Multiple Sclerosis (PMS)
  • Multiple Sclerosis - Relapsing Remitting
  • Multiple Sclerosis
  • Multiple Sclerosis (Relapsing Remitting)
  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Progressive Multiple Sclerosis

Interventions

  • CABA-201Biological

    Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary (Part A: Dose Escalation) incidence and severity of adverse eventsTime frame: Up to 28 days after CABA-201 infusion
  2. Primary (Part B: Dose Expansion) incidence of and severity of adverse events in order to confirm the dose(s) of CABA-201Time frame: Up to 28 days after CABA-201 infusion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.